CRA-026440 NEW
| Price | $700 | $1800 |
| Package | 1mg | 5mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: CRA-026440 | CAS No.: 847460-34-8 |
| Purity: 96.42% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | CRA-026440 |
| Description | CRA-026440 is a highly potent HDAC inhibitor with inhibitory effects on HDAC1, HDAC2, HDAC3, HDAC6, HDAC8 and HDAC10 with Ki values of 4,14,11,15,7 and 20 nM, respectively. CRA-026440 has anti-tumor and anti-angiogenic activity and can be used to study colon cancer. |
| In vitro | CRA-026440 exhibits anti-proliferative effects on HUVEC endothelial cells with a GI50 value of 1.41 μM[1]. In tumor cells, treatment with CRA-026440 (0.1-10 μM; 18 hours) leads to the accumulation of acetylated histones and acetylated microtubule proteins, thereby inhibiting tumor cell growth and inducing apoptosis[1]. CRA-026440 (0.1-10 μM; 5 days) inhibits ex vivo angiogenesis in a dose-dependent manner[1]. |
| In vivo | Administered intravenously at a dose of 100 mg/kg daily for three consecutive days, CRA-026440 significantly reduces tumor growth in mice bearing HCT116 or U937 human tumor xenografts[1]. |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (214.05 mM), Sonication is recommended. |
| Keywords | HDAC8 | HDAC6 | HDAC3 | HDAC2 | HDAC10 | HDAC1 | HDAC | CRA-026440 | CRA026440 | CRA 026440 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Manganese chloride (tetrahydrate) | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Histone Modification Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | ReFRAME Related Library | Epigenetics Compound Library | Post-Translational Modification Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | High-Efficiency Gene Editing Small Molecule Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $117.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-07-10 | |
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-03 | |
| $2.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 | |
| $700.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY